1
|
Dean B, Duce J, Li QX, Masters CL, Scarr E. Lower levels of soluble β-amyloid precursor protein, but not β-amyloid, in the frontal cortex in schizophrenia. Psychiatry Res 2024; 331:115656. [PMID: 38071879 DOI: 10.1016/j.psychres.2023.115656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 11/28/2023] [Accepted: 12/01/2023] [Indexed: 01/02/2024]
Abstract
We identified a sub-group (25%) of people with schizophrenia (muscarinic receptor deficit schizophrenia (MRDS)) that are characterised because of markedly lower levels of cortical muscarinic M1 receptors (CHRM1) compared to most people with the disorder (non-MRDS). Notably, bioinformatic analyses of our cortical gene expression data shows a disturbance in the homeostasis of a biochemical pathway that regulates levels of CHRM1. A step in this pathway is the processing of β-amyloid precursor protein (APP) and therefore we postulated there would be altered levels of APP in the frontal cortex from people with MRDS. Here we measure levels of CHRM1 using [3H]pirenzepine binding, soluble APP (sAPP) using Western blotting and amyloid beta peptides (Aβ1-40 and Aβ1-42) using ELISA in the frontal cortex (Brodmann's area 6: BA 6; MRDS = 14, non-MRDS = 14, controls = 14). We confirmed the MRDS cohort in this study had the expected low levels of [3H]pirenzepine binding. In addition, we showed that people with schizophrenia, independent of their sub-group status, had lower levels of sAPP compared to controls but did not have altered levels of Aβ1-40 or Aβ1-42. In conclusion, whilst changes in sAPP are not restricted to MRDS our data could indicate a role of APP, which is important in axonal and synaptic pruning, in the molecular pathology of the syndrome of schizophrenia.
Collapse
Affiliation(s)
- Brian Dean
- The Florey, Parkville, Victoria, Australia; The University of Melbourne of Melbourne Florey Department of Neuroscience and Mental Health, Parkville, Victoria, Australia.
| | - James Duce
- MSD Discovery Centre, 120 Moorgate, London, UK
| | - Qiao-Xin Li
- The Florey, Parkville, Victoria, Australia; The University of Melbourne of Melbourne Florey Department of Neuroscience and Mental Health, Parkville, Victoria, Australia
| | - Colin L Masters
- The Florey, Parkville, Victoria, Australia; The University of Melbourne of Melbourne Florey Department of Neuroscience and Mental Health, Parkville, Victoria, Australia
| | - Elizabeth Scarr
- The Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia
| |
Collapse
|
2
|
Boffey H, Rooney TPC, Willems HMG, Edwards S, Green C, Howard T, Ogg D, Romero T, Scott DE, Winpenny D, Duce J, Skidmore J, Clarke JH, Andrews SP. Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase γ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode. J Med Chem 2022; 65:3359-3370. [PMID: 35148092 PMCID: PMC9097471 DOI: 10.1021/acs.jmedchem.1c01819] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Indexed: 12/31/2022]
Abstract
Phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are emerging as attractive therapeutic targets in diseases, such as cancer, immunological disorders, and neurodegeneration, owing to their central role in regulating cell signaling pathways that are either dysfunctional or can be modulated to promote cell survival. Different modes of binding may enhance inhibitor selectivity and reduce off-target effects in cells. Here, we describe efforts to improve the physicochemical properties of the selective PI5P4Kγ inhibitor, NIH-12848 (1). These improvements enabled the demonstration that this chemotype engages PI5P4Kγ in intact cells and that compounds from this series do not inhibit PI5P4Kα or PI5P4Kβ. Furthermore, the first X-ray structure of PI5P4Kγ bound to an inhibitor has been determined with this chemotype, confirming an allosteric binding mode. An exemplar from this chemical series adopted two distinct modes of inhibition, including through binding to a putative lipid interaction site which is 18 Å from the ATP pocket.
Collapse
Affiliation(s)
- Helen
K. Boffey
- The
ALBORADA Drug Discovery Institute, University
of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, U.K.
| | - Timothy P. C. Rooney
- The
ALBORADA Drug Discovery Institute, University
of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, U.K.
| | - Henriette M. G. Willems
- The
ALBORADA Drug Discovery Institute, University
of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, U.K.
| | - Simon Edwards
- The
ALBORADA Drug Discovery Institute, University
of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, U.K.
| | - Christopher Green
- UK
Dementia Research Institute, University
of Cambridge, Island
Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, U.K.
| | - Tina Howard
- Peak
Proteins, Alderley Park, Macclesfield SK10 4TG, Cheshire, U.K.
| | - Derek Ogg
- Peak
Proteins, Alderley Park, Macclesfield SK10 4TG, Cheshire, U.K.
| | - Tamara Romero
- The
ALBORADA Drug Discovery Institute, University
of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, U.K.
| | - Duncan E. Scott
- The
ALBORADA Drug Discovery Institute, University
of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, U.K.
| | - David Winpenny
- The
ALBORADA Drug Discovery Institute, University
of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, U.K.
| | - James Duce
- The
ALBORADA Drug Discovery Institute, University
of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, U.K.
| | - John Skidmore
- The
ALBORADA Drug Discovery Institute, University
of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, U.K.
| | - Jonathan H. Clarke
- The
ALBORADA Drug Discovery Institute, University
of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, U.K.
| | - Stephen P. Andrews
- The
ALBORADA Drug Discovery Institute, University
of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, U.K.
| |
Collapse
|
3
|
Moreau C, Rolland AS, Pioli E, Li Q, Odou P, Barthelemy C, Lannoy D, Demailly A, Carta N, Deramecourt V, Auger F, Kuchcinski G, Laloux C, Defebvre L, Bordet R, Duce J, Devedjian JC, Bezard E, Fisichella M, Devos D. Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease. Neurobiol Dis 2020; 139:104846. [DOI: 10.1016/j.nbd.2020.104846] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Revised: 02/24/2020] [Accepted: 03/18/2020] [Indexed: 12/27/2022] Open
|
4
|
Moreau C, Danel V, Devedjian JC, Grolez G, Timmerman K, Laloux C, Petrault M, Gouel F, Jonneaux A, Dutheil M, Lachaud C, Lopes R, Kuchcinski G, Auger F, Kyheng M, Duhamel A, Pérez T, Pradat PF, Blasco H, Veyrat-Durebex C, Corcia P, Oeckl P, Otto M, Dupuis L, Garçon G, Defebvre L, Cabantchik ZI, Duce J, Bordet R, Devos D. Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis? Antioxid Redox Signal 2018; 29:742-748. [PMID: 29287521 PMCID: PMC6067092 DOI: 10.1089/ars.2017.7493] [Citation(s) in RCA: 77] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Iron accumulation has been observed in mouse models and in both sporadic and familial forms of amyotrophic lateral sclerosis (ALS). Iron chelation could reduce iron accumulation and the related excess of oxidative stress in the motor pathways. However, classical iron chelation would induce systemic iron depletion. We assess the safety and efficacy of conservative iron chelation (i.e., chelation with low risk of iron depletion) in a murine preclinical model and pilot clinical trial. In Sod1G86R mice, deferiprone increased the mean life span compared with placebo. The safety was good, without anemia after 12 months of deferiprone in the 23 ALS patients enrolled in the clinical trial. The decreases in the ALS Functional Rating Scale and the body mass index were significantly smaller for the first 3 months of deferiprone treatment (30 mg/kg/day) than for the first treatment-free period. Iron levels in the cervical spinal cord, medulla oblongata, and motor cortex (according to magnetic resonance imaging), as well as cerebrospinal fluid levels of oxidative stress and neurofilament light chains were lower after deferiprone treatment. Our observation leads to the hypothesis that moderate iron chelation regimen that avoids changes in systemic iron levels may constitute a novel therapeutic modality of neuroprotection for ALS. Antioxid. Redox Signal. 29, 742-748.
Collapse
Affiliation(s)
- Caroline Moreau
- 1 Department of Neurology, ALS Center, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France
| | - Véronique Danel
- 1 Department of Neurology, ALS Center, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France
| | - Jean Christophe Devedjian
- 2 Department of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France
| | - Guillaume Grolez
- 1 Department of Neurology, ALS Center, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France
| | - Kelly Timmerman
- 2 Department of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France
| | - Charlotte Laloux
- 2 Department of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France
| | - Maud Petrault
- 2 Department of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France
| | - Flore Gouel
- 2 Department of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France
| | - Aurélie Jonneaux
- 2 Department of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France
| | - Mary Dutheil
- 2 Department of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France
| | - Cédrick Lachaud
- 2 Department of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France
| | - Renaud Lopes
- 3 Department of Neuroradiology, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France
| | - Grégory Kuchcinski
- 3 Department of Neuroradiology, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France
| | - Florent Auger
- 4 Department of Preclinical Radiology, Lille University , INSERM UMRS_1171, LICEND COEN Center, Lille, France
| | - Maeva Kyheng
- 5 Department of Biostatistic, University of Lille , CHU Lille, EA 2694-Santé Publique: épidémiologie et qualité des soins, Lille, France
| | - Alain Duhamel
- 5 Department of Biostatistic, University of Lille , CHU Lille, EA 2694-Santé Publique: épidémiologie et qualité des soins, Lille, France
| | - Thierry Pérez
- 6 Department of Pneumology, Lille University, University Hospital Center , Lille, France
| | - Pierre François Pradat
- 7 Laboratoire d'Imagerie Biomédicale, Sorbonne Universités, UPMC University Paris 06 , CNRS, Inserm, Paris, France .,8 Département de Neurologie, AP-HP, Hôpital Pitié-Salpêtrière , Paris, France
| | - Hélène Blasco
- 9 Laboratoire de Biochimie, Université François Rabelais , INSERM U930, CHRU, Tours, France
| | | | - Philippe Corcia
- 9 Laboratoire de Biochimie, Université François Rabelais , INSERM U930, CHRU, Tours, France
| | - Patrick Oeckl
- 10 Department of Neurology, Center for Biomedical Research, Ulm University Hospital , Ulm, Germany
| | - Markus Otto
- 10 Department of Neurology, Center for Biomedical Research, Ulm University Hospital , Ulm, Germany
| | - Luc Dupuis
- 11 INSERM UMR-S1118, Faculté de Médecine de , Strasbourg, France
| | - Guillaume Garçon
- 12 EA4483 Department of Toxicology, CHU of Lille University , Lille, France
| | - Luc Defebvre
- 1 Department of Neurology, ALS Center, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France
| | - Z Ioav Cabantchik
- 13 Della Pergola Chair, Alexander Silberman Institute of Life Sciences, Hebrew University , Jerusalem, Israel
| | - James Duce
- 14 Alzheimer's Research UK Cambridge Drug Discovery Institute, University of Cambridge , Cambridge Biomedical Campus, Cambridge, United Kingdom .,15 The Florey Institute of Neuroscience and Mental Health, University of Melbourne , Parkville, Victoria, Australia
| | - Régis Bordet
- 2 Department of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France
| | - David Devos
- 1 Department of Neurology, ALS Center, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France .,2 Department of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center , LICEND COEN Center, Lille, France
| |
Collapse
|
5
|
Soon CPW, Donnelly PS, Turner BJ, Hung LW, Crouch PJ, Sherratt NA, Tan JL, Lim NKH, Lam L, Bica L, Lim S, Hickey JL, Morizzi J, Powell A, Finkelstein DI, Culvenor JG, Masters CL, Duce J, White AR, Barnham KJ, Li QX. Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J Biol Chem 2011; 286:44035-44044. [PMID: 22033929 DOI: 10.1074/jbc.m111.274407] [Citation(s) in RCA: 109] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive paralyzing disease characterized by tissue oxidative damage and motor neuron degeneration. This study investigated the in vivo effect of diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)), which is an orally bioavailable, blood-brain barrier-permeable complex. In vitro the compound inhibits the action of peroxynitrite on Cu,Zn-superoxide dismutase (SOD1) and subsequent nitration of cellular proteins. Oral treatment of transgenic SOD1G93A mice with CuII(atsm) at presymptomatic and symptomatic ages was performed. The mice were examined for improvement in lifespan and motor function, as well as histological and biochemical changes to key disease markers. Systemic treatment of SOD1G93A mice significantly delayed onset of paralysis and prolonged lifespan, even when administered to symptomatic animals. Consistent with the properties of this compound, treated mice had reduced protein nitration and carbonylation, as well as increased antioxidant activity in spinal cord. Treatment also significantly preserved motor neurons and attenuated astrocyte and microglial activation in mice. Furthermore, CuII(atsm) prevented the accumulation of abnormally phosphorylated and fragmented TAR DNA-binding protein-43 (TDP-43) in spinal cord, a protein pivotal to the development of ALS. CuII(atsm) therefore represents a potential new class of neuroprotective agents targeting multiple major disease pathways of motor neurons with therapeutic potential for ALS.
Collapse
Affiliation(s)
- Cynthia P W Soon
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010
| | - Paul S Donnelly
- School of Chemistry, The University of Melbourne, Parkville, Victoria 3010; Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010
| | - Bradley J Turner
- Centre for Neuroscience, The University of Melbourne, Parkville, Victoria 3010; Florey Neuroscience Institutes, The University of Melbourne, Parkville, Victoria 3010
| | - Lin W Hung
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010; Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010
| | - Peter J Crouch
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010; Centre for Neuroscience, The University of Melbourne, Parkville, Victoria 3010
| | - Nicki A Sherratt
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010; Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010
| | - Jiang-Li Tan
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010
| | - Nastasia K-H Lim
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010; Centre for Neuroscience, The University of Melbourne, Parkville, Victoria 3010
| | - Linh Lam
- Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010
| | - Laura Bica
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010
| | - SinChun Lim
- School of Chemistry, The University of Melbourne, Parkville, Victoria 3010; Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010
| | - James L Hickey
- School of Chemistry, The University of Melbourne, Parkville, Victoria 3010; Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010
| | - Julia Morizzi
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Andrew Powell
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - David I Finkelstein
- Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010
| | - Janetta G Culvenor
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Centre for Neuroscience, The University of Melbourne, Parkville, Victoria 3010
| | - Colin L Masters
- Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010
| | - James Duce
- Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010
| | - Anthony R White
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010; Centre for Neuroscience, The University of Melbourne, Parkville, Victoria 3010
| | - Kevin J Barnham
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010; Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010.
| | - Qiao-Xin Li
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010; Centre for Neuroscience, The University of Melbourne, Parkville, Victoria 3010.
| |
Collapse
|
6
|
Gunn A, Duce J, McLean C, Bush A, Cherny R. P3‐180: Glutaminyl cyclase activity is decreased in Alzheimer's cerebrospinal fluid. Alzheimers Dement 2011. [DOI: 10.1016/j.jalz.2011.05.1621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- Adam Gunn
- Mental Health Research InstituteUniversity of MelbourneMelbourneAustralia
| | - James Duce
- Mental Health Research InstituteUniversity of MelbourneMelbourneAustralia
| | | | - Ashley Bush
- Mental Health Research InstituteUniversity of MelbourneMelbourneAustralia
| | - Robert Cherny
- Prana Biotechnology, and The Mental Health research InstituteMelbourneAustralia
| |
Collapse
|
7
|
Duce J, Lei P, Tsatsanis A, Ayton S, Lam L, Adlard P, Ciccotosto G, Masters C, Cappai R, Barnham K, Rogers J, Finkelstein D, Bush A. O3‐05‐07: The relationship between beta‐amyloid protein precursor and tau in Alzheimer's disease‐related iron disruption. Alzheimers Dement 2011. [DOI: 10.1016/j.jalz.2011.05.1422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- James Duce
- Mental Health Research InstituteMelbourneAustralia
| | - Peng Lei
- Mental Health Research InstituteMelbourneAustralia
| | | | - Scott Ayton
- Mental Health Research InstituteMelbourneAustralia
| | - Linh Lam
- Mental Health Research InstituteMelbourneAustralia
| | - Paul Adlard
- The Mental Health Research InstituteMelbourneAustralia
| | | | | | | | | | - Jack Rogers
- Massachusetts General HospitalCharlestownMassachusettsUnited States
| | | | - Ashley Bush
- Mental Health Research InstituteUniversity of MelbourneMelbourneAustralia
| |
Collapse
|
8
|
Lei P, Ayton S, Wright D, Ciccotosto G, Cappai R, Duce J, Finkelstein D, Bush A. O4‐08‐03: Loss of tau induces age‐dependent neurodegeneration. Alzheimers Dement 2011. [DOI: 10.1016/j.jalz.2011.09.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Peng Lei
- Mental Health Research InstituteParkvilleAustralia
| | - Scott Ayton
- Mental Health Research InstituteMelbourneAustralia
| | | | | | | | - James Duce
- Mental Health Research InstituteMelbourneAustralia
| | | | - Ashley Bush
- Mental Health Research Institute, The University of MelbourneParkvilleAustralia
| |
Collapse
|
9
|
Watanabe S, Nagano S, Duce J, Kiaei M, Li QX, Tucker SM, Tiwari A, Brown RH, Beal MF, Hayward LJ, Culotta VC, Yoshihara S, Sakoda S, Bush AI. Increased affinity for copper mediated by cysteine 111 in forms of mutant superoxide dismutase 1 linked to amyotrophic lateral sclerosis. Free Radic Biol Med 2007; 42:1534-42. [PMID: 17448900 DOI: 10.1016/j.freeradbiomed.2007.02.004] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2006] [Revised: 02/04/2007] [Accepted: 02/12/2007] [Indexed: 11/27/2022]
Abstract
Mutations in Cu,Zn-superoxide dismutase (SOD1) cause familial amyotrophic lateral sclerosis (ALS). It has been proposed that neuronal cell death might occur due to inappropriately increased Cu interaction with mutant SOD1. Using Cu immobilized metal-affinity chromatography (IMAC), we showed that mutant SOD1 (A4V, G85R, and G93A) expressed in transfected COS7 cells, transgenic mouse spinal cord tissue, and transformed yeast possessed higher affinity for Cu than wild-type SOD1. Serine substitution for cysteine at the Cys111 residue in mutant SOD1 abolished the Cu interaction on IMAC. C111S substitution reversed the accelerated degradation of mutant SOD1 in transfected cells, suggesting that the Cys111 residue is critical for the stability of mutant SOD1. Aberrant Cu binding at the Cys111 residue may be a significant factor in altering mutant SOD1 behavior and may explain the benefit of controlling Cu access to mutant SOD1 in models of familial ALS.
Collapse
Affiliation(s)
- Shohei Watanabe
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Boutell JM, Thomas P, Neal JW, Weston VJ, Duce J, Harper PS, Jones AL. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum Mol Genet 1999; 8:1647-55. [PMID: 10441327 DOI: 10.1093/hmg/8.9.1647] [Citation(s) in RCA: 206] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
We detected an interaction of the N-terminus of huntingtin (htt171) with the C-terminal region of the nuclear receptor co-repressor (N-CoR) using the yeast two-hybrid system. This interaction was repeat length dependent and specific to htt171; the co-repressor did not interact with the repeat carrying a section of atrophin 1 nor with the androgen receptor or polyglutamine alone. The interaction was confirmed using His-tagged Escherichia coli -expressed C-terminal human and rat co-repressor protein which pulled full-length huntingtin out of homogenized rat brain and in pull-down assays. The N-CoR represses transcription from sequence-specific ligand-activated receptors such as the retinoid X-thyroid hormone receptor dimers and other nuclear receptors including Mad-Max receptor dimers. The mechanism of this repression appears to be through the formation of a complex of repressor proteins including the N-CoR, mSin3 and histone deacetylases. We have used N-CoR and mSin3A antibodies in immunohistochemical studies and find that in Huntington's disease (HD) cortex and caudate, the cellular localization of these proteins is exclusively cytoplasmic whilst in control brain they are localized in the nucleus as well as the cytoplasm; mSin3A immunoreactivity also occurred in a subset of huntingtin positive intranuclear inclusions. The relocalization of repressor proteins in HD brain may alter transcription and be involved in the pathology of the disease.
Collapse
Affiliation(s)
- J M Boutell
- Institute of Medical Genetics, University of Wales College of Medicine, Cardiff, UK
| | | | | | | | | | | | | |
Collapse
|